Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA's Gottlieb: 'Pricing And Reimbursement Mischief' Holding Back Biosimilar Market

Executive Summary

The FDA Commissioner called on payers to take steps to build the US biosimilar market and discouraged some early contracting schemes, calling them pay-for-delay tactics "dressed in the guise of rebates" in a notable speech at AHIP.


Related Content

Merck Steps Out Of Insulin Glargine Market, But Says It Remains Committed To Biosimilars
Enthusiasm For US Biosimilars Wanes For Some, But Not Others
FDA Commissioner’s Rx For US Biosimilars Market: Reform Contracting Practices And Payment Models
As J&J Sees Continued Drug Price Declines, CEO Urges Slow Policy Change Via Trump's Blueprint
Biosimilars For US Market May Be Able To Rely On EU-Licensed Reference Products
Mylan's Fulphila Sets Up The US Market For The Next Biosimilar Showdown
End In Sight: Humira Stacks Up 20 Years Of US Market Exclusivity
Payers Like Biosimilars, But Rebates Remain The Bottom Line (For Now)
Payers Could Guarantee Biosimilar Market Share, FDA's Gottlieb Suggests
Pfizer Sets The Stage For A Biosimilar Showdown Over Exclusive Contracts


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts